Lopes M Beatriz S
Departments of Pathology and Neurological Surgery, University of Virginia School of Medicine, Charlottesville, VA, United States.
Handb Clin Neurol. 2018;149:67-73. doi: 10.1016/B978-0-12-811161-1.00005-0.
A large percentage of patients with cancer will develop brain metastases, and many of them will die within a few months following diagnosis of intracranial metastasis. Although the majority of the central nervous system metastases are derived from a well-known primary neoplasm, about 5-10% of brain metastases are from an unknown source, making the tissue diagnosis a first step in the search for a primary malignancy. The pathologist utilizes several immunohistochemical and molecular diagnostic tools for such investigation, helping the clinical oncologist to narrow down the clinical and radiologic exploration. Recently, analysis of actionable biomarkers for target therapy in brain metastasis has become significant due to reports of discrepancy of potential biomarkers between primary tumors and metastatic brain deposits.
很大比例的癌症患者会发生脑转移,其中许多人在颅内转移诊断后的几个月内死亡。虽然大多数中枢神经系统转移瘤源自已知的原发性肿瘤,但约5%-10%的脑转移瘤来源不明,这使得组织诊断成为寻找原发性恶性肿瘤的第一步。病理学家利用多种免疫组织化学和分子诊断工具进行此类研究,帮助临床肿瘤学家缩小临床和影像学检查范围。最近,由于有报道称原发性肿瘤和脑转移瘤中潜在生物标志物存在差异,因此分析脑转移瘤中可用于靶向治疗的可操作生物标志物变得至关重要。